Caribou Biosciences initiates Phase 1 trial for CB-010 in lupus patients

From GlobeNewswire: 2025-01-12 19:05:00

Caribou Biosciences, Inc. has initiated the GALLOP Phase 1 clinical trial to evaluate CB-010 in patients with lupus nephritis and extrarenal lupus. The company also provided an outlook on multiple clinical data catalysts planned for 2025. In addition to the GALLOP trial, Caribou highlighted successful execution across its three clinical-stage allogeneic CAR-T cell therapy programs in hematologic malignancies. The company’s CEO expressed excitement about the progress made in 2024 and the upcoming clinical data expected in the first half of 2025.

Caribou has completed dose level 3 in the AMpLify Phase 1 trial for r/r AML with no DLTs and is now enrolling patients at dose level 4. Clinical data from the CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 trials are expected in the first half of 2025. Sri Ryali has been appointed as the company’s chief financial officer, and Caribou will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 16th at 10:30 am PST.



Read more at GlobeNewswire: Caribou Biosciences Initiates the CB-010 GALLOP Phase 1